Shire Pharma Canada ULC (Shire Canada) celebrated their official opening of their new offices in downtown Toronto last Thursday. The new location is located Canada’s largest biotech cluster, offering a range of opportunities for collaboration and partnership.
The Toronto region is home to more than 11,000 principal researchers and technicians, 37 research institutes, eight universities and colleges, world-class research hospitals and numerous private sector research facilities.
“Our new Toronto location provides access to a thriving life sciences sector and is a great base from which to attract talent for the organization,” said Eric Tse, general manager for Shire Canada. “It will also serve to promote closer collaboration and strengthen relationships with key external stakeholders in academic research, clinical practice, patient advocacy and medical innovation.”
Founded more than 30 years ago, Shire is biotechnology company focused on serving people with rare diseases and other highly specialized conditions. It is estimated that one in 12 Canadians has a rare disorder.
“I am delighted that Shire Canada has chosen Toronto as its new Canadian base,” said Reza Moridi, Ontario Minister of Research, Innovation, and Science. “Shire Canada has shown it recognizes Ontario’s talented workforce as a source of competitive advantage. “
Most rare diseases are genetic and pose a significant medical, economic and societal burden for patients, communities and the healthcare system.
As many as 7,000 rare diseases have been identified yet few than five per cent of them have treatments available for patients who need them.
Shire Pharma Canada ULC is a subsidiary of Shire.